Responses to CPET in Subjects With Persistent Exercise Intolerance After COVID-19: an Open-Source Exercise Network

NCT ID: NCT05532995

Last Updated: 2024-05-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-07-15

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This retrospective collaborative study on persistent exercise intolerance after COVID-19 offers to perform a large descriptive analysis of CPET performed in real-life by pulmonologists, cardiologists and physiologists. Indeed, these practicians are regularly consulted for a persistent intolerance to exercise expressed by dyspnea and/or frank fatigability sometimes associated with muscular or thoracic pain. When these complaints persist beyond 3 months after the first symptoms, it is legitimate to perform a CPET:

* Either to evaluate the functional impact of an identified organ deficiency (e.g. myocarditis, pulmonary fibrosis, etc.),
* Or, in the absence of formal arguments for an identified organ deficiency, to observe possible abnormalities in physiological responses during an incremental exercise test, likely to explain the persistence of symptoms and intolerance to exercise. Indeed, the recent literature highlights the presence of non-specific ventilatory and cardio-circulatory abnormalities leading to various physio-pathological observations. Unfortunately, these reports now concern relatively small numbers of patients with very diverse clinical forms of Covid, comorbidities and habitus.

In order to improve the understanding of persistent symptoms and in particular the diversity of physiological response presentations, the investigators propose to collect a very large amount of data through a web-based platform designed to collect the measurements made throughout the exercise test directly from the ergospirometer.

The relevant data covers the period from January 2, 2020 to December 31, 2022 (i.e. 35 months), The retrospective data collection will be carried out from February 1, 2023 to December 31, 2023.

The descriptive analysis will focus on the kinetics of all the variables measured and calculated on subgroups defined a priori on age, sex, comorbidities, acute covid severity, persistent symptoms post covid, regular habitual physical activity level, etc. according to the sample.

The study is expected to collect data from around 1000 patients and to involve around 40 French-speaking investigators. However, this collaborative study is open on request to all centers wishing to participate, as the web platform has been developed for data collection in English.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* Patients with persistent symptoms 3 months after the onset of Covid-19 infection, regardless the severity of the initial illness
* Patients with an ICU stay, primarily following rehabilitation management; that is, in practice, at least 6 months after COVID
* Patients followed by a pulmonologist, cardiologist or physiologist in a public or private facility or in private practice, allowing for CPET
* Patients who have performed a CPET before December 31, 2023
* Patients informed of the possible anonymized processing of the data collected during CPET for research purposes; and who gave informed consent

Exclusion Criteria

* Age \< 18 years
* Patients unable to perform CPET for locomotor reasons
* Patients with severely reduced functional work capacity
* Patient deprived of liberty by judicial or administrative decision
* Patients unable to give informed consent
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Menarini Group

INDUSTRY

Sponsor Role collaborator

Hylab, Grenoble

OTHER

Sponsor Role collaborator

AstraZeneca

INDUSTRY

Sponsor Role collaborator

Association pour la Complementarite des Connaissances et des Pratiques de la Pneumologie

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bernard Aguilaniu, M.D. PhD

Role: STUDY_DIRECTOR

Association pour la Complementarite des Connaissances et des Pratiques de la Pneumologie

PierAntonio Laveneziana, M.D. PhD

Role: PRINCIPAL_INVESTIGATOR

University Hospital La Pitié-Salpêtrière

Frédéric Costes, M.D. PhD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Clermont-Ferrand

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hosp. Maisonneuve-Rosemont

Montreal, , Canada

Site Status

University Hosp. Amiens-Picardie

Amiens, , France

Site Status

Angers University Hosp.

Angers, , France

Site Status

AP-HP University Hosp. Avicenne

Bobigny, , France

Site Status

Brest University Hosp. Cavale Blanche

Brest, , France

Site Status

Hosp. Louis Pradel

Bron, , France

Site Status

SSR Marguerite Boucicaut French Red Cross

Chalon-sur-Saône, , France

Site Status

University Hosp. Gabriel-Montpied

Clermont-Ferrand, , France

Site Status

Corbie General Hosp. (Réadaptation)

Corbie, , France

Site Status

Centre de Réadaptation Cardio-Respiratoire Dieulefit Santé

Dieulefit, , France

Site Status

Centre Médical Bayère

Gleizé, , France

Site Status

Grenoble Alpes University Hosp. Michallon Nord

Grenoble, , France

Site Status

Grenoble Alpes University Hosp. Michallon Sud

Grenoble, , France

Site Status

Hosp. St Philibert GH Catholique Institute Lille

Lille, , France

Site Status

Limoges General Hosp.

Limoges, , France

Site Status

Medical Center Parot

Lyon, , France

Site Status

Médipôle Lyon-Villeurbanne

Lyon, , France

Site Status

Nice University Hosp. Pasteur

Nice, , France

Site Status

Clinique Les Rieux

Nyons, , France

Site Status

AP-HP Hôpital Bichat Claude-Bernard

Paris, , France

Site Status

AP-HP University Hosp. Cochin

Paris, , France

Site Status

AP-HP University Hosp. Pitié Salpêtrière

Paris, , France

Site Status

Polyclinique Les Bleuets

Reims, , France

Site Status

University Hosp. of Pontchaillou

Rennes, , France

Site Status

Rouen University Hosp. Charles-Nicolle

Rouen, , France

Site Status

Toulouse University Hosp.

Toulouse, , France

Site Status

Tours University Hosp. Bretonneau

Tours, , France

Site Status

Clinique Saint Paul

Fort-de-France, , Martinique

Site Status

Geneva University Hosp.

Geneva, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada France Martinique Switzerland

References

Explore related publications, articles, or registry entries linked to this study.

Gao Y, Chen R, Geng Q, Mo X, Zhan C, Jian W, Li S, Zheng J. Cardiopulmonary exercise testing might be helpful for interpretation of impaired pulmonary function in recovered COVID-19 patients. Eur Respir J. 2021 Jan 28;57(1):2004265. doi: 10.1183/13993003.04265-2020. Print 2021 Jan.

Reference Type BACKGROUND
PMID: 33361097 (View on PubMed)

Cortes-Telles A, Lopez-Romero S, Figueroa-Hurtado E, Pou-Aguilar YN, Wong AW, Milne KM, Ryerson CJ, Guenette JA. Pulmonary function and functional capacity in COVID-19 survivors with persistent dyspnoea. Respir Physiol Neurobiol. 2021 Jun;288:103644. doi: 10.1016/j.resp.2021.103644. Epub 2021 Feb 27.

Reference Type BACKGROUND
PMID: 33647535 (View on PubMed)

Gervasi SF, Pengue L, Damato L, Monti R, Pradella S, Pirronti T, Bartoloni A, Epifani F, Saggese A, Cuccaro F, Bianco M, Zeppilli P, Palmieri V. Is extensive cardiopulmonary screening useful in athletes with previous asymptomatic or mild SARS-CoV-2 infection? Br J Sports Med. 2021 Jan;55(1):54-61. doi: 10.1136/bjsports-2020-102789. Epub 2020 Oct 5.

Reference Type BACKGROUND
PMID: 33020140 (View on PubMed)

Mohr A, Dannerbeck L, Lange TJ, Pfeifer M, Blaas S, Salzberger B, Hitzenbichler F, Koch M. Cardiopulmonary exercise pattern in patients with persistent dyspnoea after recovery from COVID-19. Multidiscip Respir Med. 2021 Jan 25;16(1):732. doi: 10.4081/mrm.2021.732. eCollection 2021 Jan 15.

Reference Type BACKGROUND
PMID: 33623700 (View on PubMed)

Townsend L, Moloney D, Finucane C, McCarthy K, Bergin C, Bannan C, Kenny RA. Fatigue following COVID-19 infection is not associated with autonomic dysfunction. PLoS One. 2021 Feb 25;16(2):e0247280. doi: 10.1371/journal.pone.0247280. eCollection 2021.

Reference Type BACKGROUND
PMID: 33630906 (View on PubMed)

Motiejunaite J, Balagny P, Arnoult F, Mangin L, Bancal C, d'Ortho MP, Frija-Masson J. Hyperventilation: A Possible Explanation for Long-Lasting Exercise Intolerance in Mild COVID-19 Survivors? Front Physiol. 2021 Jan 18;11:614590. doi: 10.3389/fphys.2020.614590. eCollection 2020.

Reference Type BACKGROUND
PMID: 33536937 (View on PubMed)

Debeaumont D, Boujibar F, Ferrand-Devouge E, Artaud-Macari E, Tamion F, Gravier FE, Smondack P, Cuvelier A, Muir JF, Alexandre K, Bonnevie T. Cardiopulmonary Exercise Testing to Assess Persistent Symptoms at 6 Months in People With COVID-19 Who Survived Hospitalization: A Pilot Study. Phys Ther. 2021 Jun 1;101(6):pzab099. doi: 10.1093/ptj/pzab099.

Reference Type BACKGROUND
PMID: 33735374 (View on PubMed)

Dorelli G, Braggio M, Gabbiani D, Busti F, Caminati M, Senna G, Girelli D, Laveneziana P, Ferrari M, Sartori G, Dalle Carbonare L, Crisafulli E, On Behalf Of The Respicovid Study Investigators. Importance of Cardiopulmonary Exercise Testing amongst Subjects Recovering from COVID-19. Diagnostics (Basel). 2021 Mar 12;11(3):507. doi: 10.3390/diagnostics11030507.

Reference Type BACKGROUND
PMID: 33809260 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Informed Consent Form

View Document

Study Documents

Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.

Document Type: Informed Consent Form

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ACCPP-PROT2022-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

COPD in the Time of COVID-19
NCT04407598 UNKNOWN